Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SPRUCE BIOSCIENCES, INC.SPRB · Entity 6471 | PRESIDENT AND CFO | December 15, 2025 | December 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SPRUCE BIOSCIENCES, INC.
Report date December 15, 2025 · Filed December 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,263 |
Ending reported balance
After 2025-12-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2025-12-15 · Exercise / conversion · Acquired 496 · Balance 8,112 F1: On December 5, 2022, the Reporting Person was granted 1,986 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 496 RSUs vested, with 178 shares withheld for taxes, resulting in a net issuance of 318 shares. F2: Each RSU represents a contingent right to receive one share of common stock of the Issuer. Row 2 · 2025-12-15 · Tax withholding · Disposed 178 · Balance 7,934 F1: On December 5, 2022, the Reporting Person was granted 1,986 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 496 RSUs vested, with 178 shares withheld for taxes, resulting in a net issuance of 318 shares. Row 3 · 2025-12-15 · Exercise / conversion · Acquired 513 · Balance 8,447 F3: On December 14, 2023, the Reporting Person was granted a total of 4,106 RSUs. 50% or 2,053 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 2,053 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 513 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 329 shares. F2: Each RSU represents a contingent right to receive one share of common stock of the Issuer. Row 4 · 2025-12-15 · Tax withholding · Disposed 184 · Balance 8,263 F3: On December 14, 2023, the Reporting Person was granted a total of 4,106 RSUs. 50% or 2,053 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 2,053 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 513 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 329 shares. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 497 |
Reported balance
After 2025-12-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-12-15 · Exercise / conversion · Disposed 496 · Balance 497 F2: Each RSU represents a contingent right to receive one share of common stock of the Issuer. F1: On December 5, 2022, the Reporting Person was granted 1,986 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 496 RSUs vested, with 178 shares withheld for taxes, resulting in a net issuance of 318 shares. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 1,027 |
Reported balance
After 2025-12-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-12-15 · Exercise / conversion · Disposed 513 · Balance 1,027 F2: Each RSU represents a contingent right to receive one share of common stock of the Issuer. F3: On December 14, 2023, the Reporting Person was granted a total of 4,106 RSUs. 50% or 2,053 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 2,053 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 513 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 329 shares. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 5, 2022, the Reporting Person was granted 1,986 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 496 RSUs vested, with 178 shares withheld for taxes, resulting in a net issuance of 318 shares.
F2: Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F3: On December 14, 2023, the Reporting Person was granted a total of 4,106 RSUs. 50% or 2,053 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 2,053 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 513 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 329 shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2025 Filed Dec 17, 2025 21:58 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 513 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001533302-25-000011 · form4-12172025_091247.xml · derivative · entry 6 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,027 Underlying: Common Stock · 513 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: On December 14, 2023, the Reporting Person was granted a total of 4,106 RSUs. 50% or 2,053 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 2,053 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 513 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 329 shares. F3 · derivative.expiration_date: On December 14, 2023, the Reporting Person was granted a total of 4,106 RSUs. 50% or 2,053 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 2,053 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 513 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 329 shares. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:58 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 496 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001533302-25-000011 · form4-12172025_091247.xml · derivative · entry 5 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 497 Underlying: Common Stock · 496 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of the Issuer. F1 · derivative.exercise_date: On December 5, 2022, the Reporting Person was granted 1,986 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 496 RSUs vested, with 178 shares withheld for taxes, resulting in a net issuance of 318 shares. F1 · derivative.expiration_date: On December 5, 2022, the Reporting Person was granted 1,986 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 496 RSUs vested, with 178 shares withheld for taxes, resulting in a net issuance of 318 shares. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:58 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 184 | $80.67 | $14,843.28 |
DisclosureSEC source: 0001533302-25-000011 · form4-12172025_091247.xml · nonDerivative · entry 4 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,263 F3 · shares: On December 14, 2023, the Reporting Person was granted a total of 4,106 RSUs. 50% or 2,053 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 2,053 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 513 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 329 shares. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:58 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 513 | $0.00 | $0.00 |
DisclosureSEC source: 0001533302-25-000011 · form4-12172025_091247.xml · nonDerivative · entry 3 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: On December 14, 2023, the Reporting Person was granted a total of 4,106 RSUs. 50% or 2,053 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 2,053 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 513 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 329 shares. F2 · price: Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:58 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 178 | $80.67 | $14,359.26 |
DisclosureSEC source: 0001533302-25-000011 · form4-12172025_091247.xml · nonDerivative · entry 2 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,934 F1 · shares: On December 5, 2022, the Reporting Person was granted 1,986 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 496 RSUs vested, with 178 shares withheld for taxes, resulting in a net issuance of 318 shares. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:58 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 496 | $0.00 | $0.00 |
DisclosureSEC source: 0001533302-25-000011 · form4-12172025_091247.xml · nonDerivative · entry 1 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On December 5, 2022, the Reporting Person was granted 1,986 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 496 RSUs vested, with 178 shares withheld for taxes, resulting in a net issuance of 318 shares. F2 · price: Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 11, 2025 Filed Dec 13, 2025 00:05 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 1,900 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001533302-25-000007 · form4-12132025_121236.xml · derivative · entry 7 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,700 Underlying: Common Stock · 1,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock. F3 · derivative.exercise_date: 25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 1,900 shares vested and 680 shares were withheld for taxes, resulting in a net issuance of 1,220 shares. F3 · derivative.expiration_date: 25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 1,900 shares vested and 680 shares were withheld for taxes, resulting in a net issuance of 1,220 shares. Read SEC document |
| December 11, 2025 Filed Dec 13, 2025 00:05 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantRestricted Stock Units · Derivative | 7,600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001533302-25-000007 · form4-12132025_121236.xml · derivative · entry 6 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,600 Underlying: Common Stock · 7,600 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock. F3 · derivative.exercise_date: 25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 1,900 shares vested and 680 shares were withheld for taxes, resulting in a net issuance of 1,220 shares. F3 · derivative.expiration_date: 25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 1,900 shares vested and 680 shares were withheld for taxes, resulting in a net issuance of 1,220 shares. Read SEC document |
| December 11, 2025 Filed Dec 13, 2025 00:05 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 680 | $88.41 | $60,118.80 |
DisclosureSEC source: 0001533302-25-000007 · form4-12132025_121236.xml · nonDerivative · entry 4 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,616 F3 · shares: 25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 1,900 shares vested and 680 shares were withheld for taxes, resulting in a net issuance of 1,220 shares. Read SEC document |
| December 11, 2025 Filed Dec 13, 2025 00:05 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 1,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001533302-25-000007 · form4-12132025_121236.xml · nonDerivative · entry 3 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,296 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: 25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 1,900 shares vested and 680 shares were withheld for taxes, resulting in a net issuance of 1,220 shares. F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:54 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Disposition to issuerStock Option (Right to Buy) · Derivative | 933 | Not disclosed Strike: $344.25 | Not disclosed |
DisclosureSEC source: 0001533302-25-000009 · form4-12152025_111246.xml · derivative · entry 10 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 933 shares Expires 2032-01-02 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F5 · derivative.exercise_date: 1/48th of the shares vest on a monthly basis from January 3, 2022, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:54 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 933 | Not disclosed Strike: $104.13 | Not disclosed |
DisclosureSEC source: 0001533302-25-000009 · form4-12152025_111246.xml · derivative · entry 9 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 933 Underlying: Common Stock · 933 shares Expires 2032-01-02 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F5 · derivative.exercise_date: 1/48th of the shares vest on a monthly basis from January 3, 2022, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:54 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,933 | Not disclosed Strike: $186.00 | Not disclosed |
DisclosureSEC source: 0001533302-25-000009 · form4-12152025_111246.xml · derivative · entry 8 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,933 shares Expires 2031-12-15 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F4 · derivative.exercise_date: 1/48th of the shares vest on a monthly basis from December 16, 2021, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:54 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 1,933 | Not disclosed Strike: $104.13 | Not disclosed |
DisclosureSEC source: 0001533302-25-000009 · form4-12152025_111246.xml · derivative · entry 7 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,933 Underlying: Common Stock · 1,933 shares Expires 2031-12-15 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F4 · derivative.exercise_date: 1/48th of the shares vest on a monthly basis from December 16, 2021, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:54 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Disposition to issuerStock Option (Right to Buy) · Derivative | 733 | Not disclosed Strike: $1,506.00 | Not disclosed |
DisclosureSEC source: 0001533302-25-000009 · form4-12152025_111246.xml · derivative · entry 6 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 733 shares Expires 2031-01-27 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F1 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:54 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 733 | Not disclosed Strike: $104.13 | Not disclosed |
DisclosureSEC source: 0001533302-25-000009 · form4-12152025_111246.xml · derivative · entry 5 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 733 Underlying: Common Stock · 733 shares Expires 2031-01-27 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F1 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:54 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Disposition to issuerStock Option (Right to Buy) · Derivative | 953 | Not disclosed Strike: $230.25 | Not disclosed |
DisclosureSEC source: 0001533302-25-000009 · form4-12152025_111246.xml · derivative · entry 4 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 953 shares Expires 2030-08-06 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F1 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:54 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 953 | Not disclosed Strike: $104.13 | Not disclosed |
DisclosureSEC source: 0001533302-25-000009 · form4-12152025_111246.xml · derivative · entry 3 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 953 Underlying: Common Stock · 953 shares Expires 2030-08-06 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F1 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:54 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,579 | Not disclosed Strike: $123.00 | Not disclosed |
DisclosureSEC source: 0001533302-25-000009 · form4-12152025_111246.xml · derivative · entry 2 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,579 shares Expires 2030-06-07 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F1 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:54 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 1,579 | Not disclosed Strike: $104.13 | Not disclosed |
DisclosureSEC source: 0001533302-25-000009 · form4-12152025_111246.xml · derivative · entry 1 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,579 Underlying: Common Stock · 1,579 shares Expires 2030-06-07 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F1 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 10, 2025 Filed Dec 13, 2025 00:05 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 514 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001533302-25-000007 · form4-12132025_121236.xml · derivative · entry 5 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,539 Underlying: Common Stock · 514 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock. F1 · derivative.exercise_date: On March 14, 2024, the Reporting Person was granted a total of 2,053 RSU's. Subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date, 25% of the total number of RSUs vested on December 10, 2025, the first anniversary of the achievement of a specified clinical development objective. 25% of the total number of the RSUs will vest on each of the second, third and fourth anniversaries of such achievement. On December 10, 2025, 514 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 330 shares. F1 · derivative.expiration_date: On March 14, 2024, the Reporting Person was granted a total of 2,053 RSU's. Subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date, 25% of the total number of RSUs vested on December 10, 2025, the first anniversary of the achievement of a specified clinical development objective. 25% of the total number of the RSUs will vest on each of the second, third and fourth anniversaries of such achievement. On December 10, 2025, 514 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 330 shares. Read SEC document |
| December 10, 2025 Filed Dec 13, 2025 00:05 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 184 | $85.67 | $15,763.28 |
DisclosureSEC source: 0001533302-25-000007 · form4-12132025_121236.xml · nonDerivative · entry 2 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,396 F1 · shares: On March 14, 2024, the Reporting Person was granted a total of 2,053 RSU's. Subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date, 25% of the total number of RSUs vested on December 10, 2025, the first anniversary of the achievement of a specified clinical development objective. 25% of the total number of the RSUs will vest on each of the second, third and fourth anniversaries of such achievement. On December 10, 2025, 514 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 330 shares. Read SEC document |
| December 10, 2025 Filed Dec 13, 2025 00:05 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 514 | $0.00 | $0.00 |
DisclosureSEC source: 0001533302-25-000007 · form4-12132025_121236.xml · nonDerivative · entry 1 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On March 14, 2024, the Reporting Person was granted a total of 2,053 RSU's. Subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date, 25% of the total number of RSUs vested on December 10, 2025, the first anniversary of the achievement of a specified clinical development objective. 25% of the total number of the RSUs will vest on each of the second, third and fourth anniversaries of such achievement. On December 10, 2025, 514 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 330 shares. F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 20:15 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 2,053 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001533302-25-000004 · form4-10222025_041003.xml · derivative · entry 4 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,053 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of SPRB common stock. F1 · derivative.exercise_date: On March 14, 2024, the Reporting Person was granted 2,053 performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 661 shares were withheld for taxes, resulting in a net issuance of 1,392 shares. F1 · derivative.expiration_date: On March 14, 2024, the Reporting Person was granted 2,053 performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 661 shares were withheld for taxes, resulting in a net issuance of 1,392 shares. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 20:15 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantRestricted Stock Units · Derivative | 2,053 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001533302-25-000004 · form4-10222025_041003.xml · derivative · entry 3 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,053 Underlying: Common Stock · 2,053 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of SPRB common stock. F1 · derivative.exercise_date: On March 14, 2024, the Reporting Person was granted 2,053 performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 661 shares were withheld for taxes, resulting in a net issuance of 1,392 shares. F1 · derivative.expiration_date: On March 14, 2024, the Reporting Person was granted 2,053 performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 661 shares were withheld for taxes, resulting in a net issuance of 1,392 shares. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 20:15 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 661 | $148.16 | $97,933.76 |
DisclosureSEC source: 0001533302-25-000004 · form4-10222025_041003.xml · nonDerivative · entry 2 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,066 F1 · shares: On March 14, 2024, the Reporting Person was granted 2,053 performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 661 shares were withheld for taxes, resulting in a net issuance of 1,392 shares. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 20:15 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 2,053 | $0.00 | $0.00 |
DisclosureSEC source: 0001533302-25-000004 · form4-10222025_041003.xml · nonDerivative · entry 1 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On March 14, 2024, the Reporting Person was granted 2,053 performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 661 shares were withheld for taxes, resulting in a net issuance of 1,392 shares. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of SPRB common stock. Read SEC document |
| December 16, 2024 Filed Dec 21, 2024 01:28 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 37,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-030000 · form4-12212024_011255.xml · derivative · entry 9 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,500 Underlying: Common Stock · 37,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock. F3 · derivative.exercise_date: On December 5, 2022, the Reporting Person was granted 149,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 37,250 RSUs vested, with 13,291 shares being withheld for taxes, resulting in a net issuance of 23,959 shares. F3 · derivative.expiration_date: On December 5, 2022, the Reporting Person was granted 149,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 37,250 RSUs vested, with 13,291 shares being withheld for taxes, resulting in a net issuance of 23,959 shares. Read SEC document |
| December 16, 2024 Filed Dec 21, 2024 01:28 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 38,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-030000 · form4-12212024_011255.xml · derivative · entry 8 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,500 Underlying: Common Stock · 38,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock. F1 · derivative.exercise_date: On December 14, 2023, the Reporting Person was granted a total of 308,000 RSUs. 50% or 154,000 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 50% or 154,000 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 38,500 shares vested and 13,737 shares were withheld for taxes, resulting in a net issuance of 24,763 shares. F1 · derivative.expiration_date: On December 14, 2023, the Reporting Person was granted a total of 308,000 RSUs. 50% or 154,000 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 50% or 154,000 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 38,500 shares vested and 13,737 shares were withheld for taxes, resulting in a net issuance of 24,763 shares. F4 · balance_after: Represents the aggregate balance of time-based RSUs. Read SEC document |
| December 16, 2024 Filed Dec 21, 2024 01:28 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 13,291 | $0.39 | $5,166.21 |
DisclosureSEC source: 0001415889-24-030000 · form4-12212024_011255.xml · nonDerivative · entry 6 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,550 F3 · shares: On December 5, 2022, the Reporting Person was granted 149,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 37,250 RSUs vested, with 13,291 shares being withheld for taxes, resulting in a net issuance of 23,959 shares. Read SEC document |
| December 16, 2024 Filed Dec 21, 2024 01:28 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 37,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-030000 · form4-12212024_011255.xml · nonDerivative · entry 5 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 363,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: On December 5, 2022, the Reporting Person was granted 149,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 37,250 RSUs vested, with 13,291 shares being withheld for taxes, resulting in a net issuance of 23,959 shares. F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock. Read SEC document |
| December 16, 2024 Filed Dec 21, 2024 01:28 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 13,737 | $0.39 | $5,339.57 |
DisclosureSEC source: 0001415889-24-030000 · form4-12212024_011255.xml · nonDerivative · entry 4 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 326,591 F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 308,000 RSUs. 50% or 154,000 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 50% or 154,000 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 38,500 shares vested and 13,737 shares were withheld for taxes, resulting in a net issuance of 24,763 shares. Read SEC document |
| December 16, 2024 Filed Dec 21, 2024 01:28 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 38,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-030000 · form4-12212024_011255.xml · nonDerivative · entry 3 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 340,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 308,000 RSUs. 50% or 154,000 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 50% or 154,000 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 38,500 shares vested and 13,737 shares were withheld for taxes, resulting in a net issuance of 24,763 shares. F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock. Read SEC document |
| December 10, 2024 Filed Dec 21, 2024 01:28 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 154,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-030000 · form4-12212024_011255.xml · derivative · entry 7 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,000 Underlying: Common Stock · 154,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock. F1 · derivative.exercise_date: On December 14, 2023, the Reporting Person was granted a total of 308,000 RSUs. 50% or 154,000 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 50% or 154,000 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 38,500 shares vested and 13,737 shares were withheld for taxes, resulting in a net issuance of 24,763 shares. F1 · derivative.expiration_date: On December 14, 2023, the Reporting Person was granted a total of 308,000 RSUs. 50% or 154,000 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 50% or 154,000 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 38,500 shares vested and 13,737 shares were withheld for taxes, resulting in a net issuance of 24,763 shares. Read SEC document |
| December 10, 2024 Filed Dec 21, 2024 01:28 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 54,948 | $0.54 | $29,507.08 |
DisclosureSEC source: 0001415889-24-030000 · form4-12212024_011255.xml · nonDerivative · entry 2 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 301,828 F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 308,000 RSUs. 50% or 154,000 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 50% or 154,000 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 38,500 shares vested and 13,737 shares were withheld for taxes, resulting in a net issuance of 24,763 shares. Read SEC document |
| December 10, 2024 Filed Dec 21, 2024 01:28 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 154,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-030000 · form4-12212024_011255.xml · nonDerivative · entry 1 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 356,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 308,000 RSUs. 50% or 154,000 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 50% or 154,000 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 38,500 shares vested and 13,737 shares were withheld for taxes, resulting in a net issuance of 24,763 shares. F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 20:29 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantRestricted Stock Units · Derivative | 154,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008270 · form4-03182024_080346.xml · derivative · entry 1 Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,000 Underlying: Common Stock · 154,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of SPRB common stock. F2 · derivative.exercise_date: Subject to the Reporting Person's Continuous Service as of each such vesting date, 25% of the total number of RSUs vests upon each of the first, second, third and fourth anniversaries of the achievement of a specified clinical development objective. F2 · derivative.expiration_date: Subject to the Reporting Person's Continuous Service as of each such vesting date, 25% of the total number of RSUs vests upon each of the first, second, third and fourth anniversaries of the achievement of a specified clinical development objective. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 21:08 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantCommon Stock | 11,255 | $0.98 | $11,001.76 |
DisclosureSEC source: 0001209191-24-000336 · doc4.xml · nonDerivative · entry 1 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,776 F1 · shares: Shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The Reporting Person acquired the maximum shares allowable pursuant to Section 423 of the Internal Revenue Code. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 01:16 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 37,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059054 · doc4.xml · derivative · entry 7 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,750 Underlying: Common Stock · 37,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock. F3 · shares: On December 5, 2022, the Reporting Person was granted 149,000 time-based RSUs, subject to a 4-year vesting schedule, with 25% of the total number of RSUs to vest on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2023, 37,250 RSUs vested, with 12,882 shares being withheld for taxes, resulting in a net issuance of 24,368 shares. F3 · derivative.exercise_date: On December 5, 2022, the Reporting Person was granted 149,000 time-based RSUs, subject to a 4-year vesting schedule, with 25% of the total number of RSUs to vest on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2023, 37,250 RSUs vested, with 12,882 shares being withheld for taxes, resulting in a net issuance of 24,368 shares. F3 · derivative.expiration_date: On December 5, 2022, the Reporting Person was granted 149,000 time-based RSUs, subject to a 4-year vesting schedule, with 25% of the total number of RSUs to vest on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2023, 37,250 RSUs vested, with 12,882 shares being withheld for taxes, resulting in a net issuance of 24,368 shares. F7 · balance_after: Represents the aggregate balance of 111,750 time-based RSUs. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 01:16 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 75,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059054 · doc4.xml · derivative · entry 6 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock. F1 · shares: On December 16, 2021, the Reporting Person was granted 150,000 time-based restricted stock units ("RSUs"), all of which were fully vested as of June 30, 2023. The Reporting Person was also granted 150,000 performance-based RSUs, which vest in two equal installments upon the achievement of specified performance goals, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On November 8, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of certain specified performance goals, resulting in the vesting of 75,000 performance-based RSUs effective December 15, 2023. On December 15, 2023, 23,213 shares were withheld for taxes, resulting in a net issuance of 51,787 shares. F1 · derivative.exercise_date: On December 16, 2021, the Reporting Person was granted 150,000 time-based restricted stock units ("RSUs"), all of which were fully vested as of June 30, 2023. The Reporting Person was also granted 150,000 performance-based RSUs, which vest in two equal installments upon the achievement of specified performance goals, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On November 8, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of certain specified performance goals, resulting in the vesting of 75,000 performance-based RSUs effective December 15, 2023. On December 15, 2023, 23,213 shares were withheld for taxes, resulting in a net issuance of 51,787 shares. F1 · derivative.expiration_date: On December 16, 2021, the Reporting Person was granted 150,000 time-based restricted stock units ("RSUs"), all of which were fully vested as of June 30, 2023. The Reporting Person was also granted 150,000 performance-based RSUs, which vest in two equal installments upon the achievement of specified performance goals, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On November 8, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of certain specified performance goals, resulting in the vesting of 75,000 performance-based RSUs effective December 15, 2023. On December 15, 2023, 23,213 shares were withheld for taxes, resulting in a net issuance of 51,787 shares. F6 · balance_after: Represents the aggregate balance of 75,000 performance-based RSUs. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 01:16 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 12,882 | $1.66 | $21,384.12 |
DisclosureSEC source: 0001209191-23-059054 · doc4.xml · nonDerivative · entry 4 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,521 F3 · shares: On December 5, 2022, the Reporting Person was granted 149,000 time-based RSUs, subject to a 4-year vesting schedule, with 25% of the total number of RSUs to vest on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2023, 37,250 RSUs vested, with 12,882 shares being withheld for taxes, resulting in a net issuance of 24,368 shares. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 01:16 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 37,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059054 · doc4.xml · nonDerivative · entry 3 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: On December 5, 2022, the Reporting Person was granted 149,000 time-based RSUs, subject to a 4-year vesting schedule, with 25% of the total number of RSUs to vest on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2023, 37,250 RSUs vested, with 12,882 shares being withheld for taxes, resulting in a net issuance of 24,368 shares. F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 01:16 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 23,213 | $1.66 | $38,533.58 |
DisclosureSEC source: 0001209191-23-059054 · doc4.xml · nonDerivative · entry 2 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,153 F1 · shares: On December 16, 2021, the Reporting Person was granted 150,000 time-based restricted stock units ("RSUs"), all of which were fully vested as of June 30, 2023. The Reporting Person was also granted 150,000 performance-based RSUs, which vest in two equal installments upon the achievement of specified performance goals, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On November 8, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of certain specified performance goals, resulting in the vesting of 75,000 performance-based RSUs effective December 15, 2023. On December 15, 2023, 23,213 shares were withheld for taxes, resulting in a net issuance of 51,787 shares. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 01:16 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059054 · doc4.xml · nonDerivative · entry 1 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,366 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On December 16, 2021, the Reporting Person was granted 150,000 time-based restricted stock units ("RSUs"), all of which were fully vested as of June 30, 2023. The Reporting Person was also granted 150,000 performance-based RSUs, which vest in two equal installments upon the achievement of specified performance goals, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On November 8, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of certain specified performance goals, resulting in the vesting of 75,000 performance-based RSUs effective December 15, 2023. On December 15, 2023, 23,213 shares were withheld for taxes, resulting in a net issuance of 51,787 shares. F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock. Read SEC document |
| December 14, 2023 Filed Dec 19, 2023 01:16 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantRestricted Stock Units · Derivative | 308,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059054 · doc4.xml · derivative · entry 5 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308,000 Underlying: Common Stock · 308,000 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock. F4 · derivative.exercise_date: 154,000 of the RSUs shall vest as to 25% on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). F5 · derivative.exercise_date: 154,000 of the RSUs shall vest upon the achievement of specified performance goals, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). F4 · derivative.expiration_date: 154,000 of the RSUs shall vest as to 25% on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). F5 · derivative.expiration_date: 154,000 of the RSUs shall vest upon the achievement of specified performance goals, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). Read SEC document |
| November 08, 2023 Filed Nov 14, 2023 00:01 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantRestricted Stock Units · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-055077 · doc4.xml · derivative · entry 1 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of SPRB common stock. F2 · shares: On December 16, 2021, the Reporting Person was granted 150,000 time-based RSUs, all of which were fully vested as of June 30, 2023. The Reporting Person was also granted 150,000 performance-based RSUs, which vest in two equal installments upon the achievement of specified performance goals, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On November 8, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of certain specified performance goals, resulting in the vesting of 75,000 performance-based RSUs effective December 15, 2023. F2 · derivative.exercise_date: On December 16, 2021, the Reporting Person was granted 150,000 time-based RSUs, all of which were fully vested as of June 30, 2023. The Reporting Person was also granted 150,000 performance-based RSUs, which vest in two equal installments upon the achievement of specified performance goals, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On November 8, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of certain specified performance goals, resulting in the vesting of 75,000 performance-based RSUs effective December 15, 2023. F2 · derivative.expiration_date: On December 16, 2021, the Reporting Person was granted 150,000 time-based RSUs, all of which were fully vested as of June 30, 2023. The Reporting Person was also granted 150,000 performance-based RSUs, which vest in two equal installments upon the achievement of specified performance goals, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On November 8, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of certain specified performance goals, resulting in the vesting of 75,000 performance-based RSUs effective December 15, 2023. F3 · balance_after: Represents the aggregate balance of 75,000 performance-based RSUs. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 22:00 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-041250 · doc4.xml · derivative · entry 4 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 75,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of SPRB common stock. F4 · derivative.exercise_date: On December 16, 2021, the Reporting Person was granted 150,000 time-based RSUs. 25% of the RSUs vested on each of June 30, 2022 and December 31, 2022 and 50% vested on June 30, 2023, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). The Reporting Person was also granted 150,000 performance-based RSUs on December 16, 2021, which shall vest upon the achievement of specified performance goals. F4 · derivative.expiration_date: On December 16, 2021, the Reporting Person was granted 150,000 time-based RSUs. 25% of the RSUs vested on each of June 30, 2022 and December 31, 2022 and 50% vested on June 30, 2023, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). The Reporting Person was also granted 150,000 performance-based RSUs on December 16, 2021, which shall vest upon the achievement of specified performance goals. F5 · balance_after: Represents the aggregate balance of 150,000 performance-based RSUs. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 22:00 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 25,936 | $2.15 | $55,762.40 |
DisclosureSEC source: 0001209191-23-041250 · doc4.xml · nonDerivative · entry 3 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,366 F3 · shares: Represents shares withheld by the Issuer to satisfy a tax obligation realized by the Reporting Person upon the vesting and settlement of RSUs. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 22:00 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 75,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-041250 · doc4.xml · nonDerivative · entry 2 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of SPRB common stock. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 22:00 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantCommon Stock | 10,484 | $0.98 | $10,248.11 |
DisclosureSEC source: 0001209191-23-041250 · doc4.xml · nonDerivative · entry 1 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,302 F1 · shares: Shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.